Cancer's genetic basis has been a central focus of research since the identification of the Philadelphia chromosome in chronic myeloid leukemia, marking a pivotal shift from purely clinical to molecularly-driven understanding.  Early genetic discoveries highlighted oncogenes and tumor suppressor genes, driving the development of targeted therapies. However, the complexity of cancer, arising from diverse genetic alterations across various pathways, necessitated a more nuanced approach.  Next-generation sequencing technologies have revolutionized cancer genomics, enabling comprehensive profiling of tumor genomes, transcriptomes, and epigenomes. This has fueled the growth of personalized medicine, allowing for the identification of specific driver mutations and the selection of tailored therapies based on individual patient profiles.  Advances in liquid biopsies further enhance the potential for minimally invasive cancer detection and real-time monitoring of treatment response.  While significant strides have been made, challenges remain, including the heterogeneity of tumors, the development of resistance mechanisms, and the ethical implications of personalized medicine's high cost and accessibility.  Future research will focus on integrating multi-omics data, improving predictive models, and developing novel therapeutic strategies to enhance treatment efficacy and patient outcomes.